Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH

Overview

The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).

Full Title of Study: “A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide’s Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin, Griseofulvin and Digoxin, and Liraglutide’s Potential Influence on Intragastric pH”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: April 2007

Interventions

  • Drug: liraglutide
    • Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
  • Drug: placebo
    • Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
  • Drug: atorvastatin
    • One single dose of 40 mg. Tablet
  • Drug: lisinopril
    • One single dose of 20 mg. Tablet
  • Drug: griseofulvin
    • One single dose of 500 mg. Tablet
  • Drug: digoxin
    • One single dose of 1 mg. Tablet

Arms, Groups and Cohorts

  • Experimental: Trial period A
  • Experimental: Trial period B

Clinical Trial Outcome Measures

Primary Measures

  • Area under the curve of atorvastatin
  • Area under the curve of lisinopril
  • Area under the curve of griseofulvin
  • Area under the curve of digoxin

Secondary Measures

  • Area under the curve of liraglutide
  • Cmax, maximum concentration
  • tmax, time to reach Cmax
  • Terminal elimination rate constant
  • Intragastric pH
  • Adverse events

Participating in This Clinical Trial

Inclusion Criteria

  • Female subjects if using adequate anti-contraception or is sterile – Body Mass Index (BMI) of 18-30 kg/m^2 (both inclusive) – Good general health as judged by the investigator, based on medical history, physical examination including 12-lead ECG (electrocardiogram), vital signs and blood and urinary laboratory assessments – Willing and capable to self-administer a subcutaneous injection Exclusion Criteria:

  • History of any clinically significant renal, hepatic, cardiovascular, pulmonary, gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric disease or other major disorders that may interfere with the objectives of the trial, as judged by the investigator – Impaired renal function – Blood pressure and heart rate in supine position outside the ranges 90-140 mmHg systolic, 50-90 mmHg diastolic and heart rate 40-100 beats/min – Any clinically significant abnormal ECG – Active hepatitis B and/or active hepatitis C – Positive HIV (human immunodeficiency virus) antibodies – Known or suspected allergy to trial product(s) or related products – Use of any prescription or non-prescription medication except for paracetamol, nasal spray or drops for nasal congestion, and vitamins within 2 weeks prior to first dosing and during the entire trial period – History of alcoholism or drug abuse during the last 12 months – Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco products – Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the Investigator

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Novo Nordisk A/S
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Global Clinical Registry (GCR, 1452), Study Director, Novo Nordisk A/S

Citations Reporting on Results

Malm-Erjefalt M, Ekblom M, Vouis J, Zdravkovic M, Lennernas H. Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. Mol Pharm. 2015 Nov 2;12(11):4166-73. doi: 10.1021/acs.molpharmaceut.5b00278. Epub 2015 Oct 12.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.